Skip to main content

Xencor Inc

For the period ended Dec 31, 2024. Filed Feb 27, 2025.

View on SEC.gov

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2024 · Filed Feb 27, 2025

XNCR$39.39+2.1%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits
Contents

Power of Attorney (included on signature page herein)

POWER OF ATTORNEY

KNOW ALL MEN BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints, jointly and severally, Bassil I. Dahiyat, Ph.D. and Bart Jan Cornelissen, and each of them acting individually, his true and lawful attorney-in-fact, each with full power of substitution and resubstitution, for him in any and all capacities, to sign any and all amendments to this Annual Report on Form 10-K and to file the same, with exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith as fully to all intents and purposes as he might or could do in person, hereby ratifying and confirming all that each of said attorneys-in-fact or their substitute or substitutes may do or cause to be done by virtue hereof.

Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the Company and in the capacities and on the dates indicated.

SignatureTitleDate
/s/ BASSIL I. DAHIYAT, PH.D.Director, President & Chief Executive Officer (Principal Executive Officer)February 26, 2025
Bassil I. Dahiyat, Ph.D.
/s/ BART JAN CORNELISSENSr. Vice President & Chief Financial Officer (Principal Financial and Accounting Officer)February 26, 2025
Bart Jan Cornelissen
/s/ A. BRUCE MONTGOMERY, M.D.DirectorFebruary 26, 2025
A. Bruce Montgomery, M.D.
/s/ KURT GUSTAFSONDirectorFebruary 26, 2025
Kurt Gustafson
/s/ KEVIN C. GORMAN, PH.D.DirectorFebruary 26, 2025
Kevin C. Gorman, Ph.D.
/s/ RICHARD RANIERIDirectorFebruary 26, 2025
Richard Ranieri
/s/ ELLEN G. FEIGAL, M.D.DirectorFebruary 26, 2025
Ellen G. Feigal, M.D.
/s/ DAGMAR ROSA-BJORKESONDirectorFebruary 26, 2025
Dagmar Rosa-Bjorkeson
/s/ BARBARA KLENCKEDirectorFebruary 26, 2025
Barbara Klencke
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.